News Report | November 3, 2019
Sandoz Exits Prescription App Commercialization Deal With Pear Therapeutics
On October 15, 2019, Sandoz and Pear Therapeutics announced that Pear will assume sole responsibility for commercializing reSET® and reSET-O®, Pear’s prescription digital therapeutics (PDTs) to treat substance use disorder, and opioid use disorder, respectively. Sandoz exited the contract to focus on its core businesses.
Pear and Sandoz had previously signed a co-promotion agreement. A Sandoz spokesperson said, “At the time of the agreement announcement, Pear’s focus was on product development and not commercialization. Sandoz was chosen as a commercialization partner for reSET and reSET-O based on the company’s ability to successfully commercialize products . . .